Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma
are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with …

Purpose To explore current developments in short interfering RNA (siRNA) delivery systems
in nanooncology, in particular nanoparticles that encapsulate siRNA for targeted treatment …

PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …

Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for
oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to …

PURPOSE Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of
death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in …

Background Glioblastoma is a highly vascularised tumour and there are few treatment
options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic …

Background Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms
of the serine/threonine kinase AKT. The FAKTION trial investigated whether the addition of …

Importance Consensus is lacking as to the optimal radiotherapy dose and fractionation
schedule for treating bone metastases. Objective To assess the relative efficacy of high …

Importance Cotargeting vascular endothelial growth factor and programmed cell death 1 or
programmed cell death ligand 1 may produce anticancer activity in refractory metastatic …